NCT05399030

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-332 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo-controlled, parallel group, single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-332 in Healthy Subjects

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	ICP-332	ICP-332 will be administered as tablet
OTHER	Placebo	Matching placebo will be administered as tablet

Timeline

• Start date: 2021-08-14
• Primary completion: 2022-01-30
• Completion: 2022-02-18
• First posted: 2022-06-01
• Last updated: 2022-08-08

Locations

1 site across 1 country: China